TRUTAKNA® (atacicept) has been FDA approved for IgAN, click to learn more. FILSPARI® (sparsentan) has also been FDA approved for FSGS and more information is coming soon. Please visit our Patient Navigation tool for support.
During the 2024 Patient Summit, we were joined by 250+ patients and families who were able to gain knowledge and support surrounding their rare kidney disease and how to maintain their health.
Dr. Corey Cavanaugh, nephrologist and NephCure Specialist, presented an educational session surrounding the history of C3G, innovations that are coming, and how to best prepare.
Visit our Youtube page
NephCure is a registered non-profit (501c3) tax-exempt charitable organization. EIN # 38-3569922.
© Copyright 2024 NephCure, Inc. All rights reserved worldwide. NephCure, and the logo, are federally registered trademarks of NephCure, Inc.
EN 
ES 
